Wednesday 15 January 2025
Home      All news      Contact us      RSS     
AAP - 8 days ago

GORTEC Announces New Trial Success for Head and Neck Cancer Treatment

TOURS, France, Jan. 7, 2025 /PRNewswire/ -- GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab, Bristol Myers Squibb s anti-PD-1 therapy, as a post-operative treatment component for resected patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN), with high risk of relapse met its primary endpoint of Disease-Free...


Latest News
Hashtags:   

GORTEC

 | 

Announces

 | 

Trial

 | 

Success

 | 

Cancer

 | 

Treatment

 | 

Sources